Drug
Inca033989
Inca033989: highest development phase Phase 3, developed by Incyte. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Incyte
Trials
| Drug | Phase | Indication |
|---|---|---|
| INCA033989 NCT07623200 | Phase 3 | Essential Thrombocythemia |
| INCA033989 NCT06034002 | Phase 1 | Myeloproliferative Neoplasms |
| INCA033989 NCT07448155 | Phase 1 |
Latest
Follow Inca033989 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.